149 related articles for article (PubMed ID: 2571595)
21. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
Winkler UH; Sudik R
Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
[TBL] [Abstract][Full Text] [Related]
22. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
23. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
Creasy GW; Fisher AC; Hall N; Shangold GA
J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
[TBL] [Abstract][Full Text] [Related]
24. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
Thorneycroft lH; Gollnick H; Schellschmidt I
Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
[TBL] [Abstract][Full Text] [Related]
25. Low-dose oral contraceptives: progestin potency, androgenicity, and atherogenic potential.
Ellis J
Clin Ther; 1986; 8(6):607-18. PubMed ID: 3539347
[TBL] [Abstract][Full Text] [Related]
26. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
27. Norgestimate: overview of a monophasic formulation.
Anderson FD; Gillmer MD
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():126-32. PubMed ID: 8260971
[No Abstract] [Full Text] [Related]
28. [Side effects of third generation progestagens].
Sitruk-ware R
Contracept Fertil Sex (Paris); 1993 Apr; 21(4):295-300. PubMed ID: 12318229
[TBL] [Abstract][Full Text] [Related]
29. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
Lepot MR; Gaspard UJ
Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343
[TBL] [Abstract][Full Text] [Related]
30. OC practice guidelines: minimizing side effects.
Darney PD
Int J Fertil Womens Med; 1997; Suppl 1():158-69. PubMed ID: 9168375
[TBL] [Abstract][Full Text] [Related]
31. Metabolic effects and efficacy of a triphasic oral contraceptive (norgestimate/ethinyl estradiol).
Andolsek KM; Burkman RT; Kafrissen ME; Olson W; Osterman J
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():122-5. PubMed ID: 8260970
[No Abstract] [Full Text] [Related]
32. Effect of oral versus transdermal steroidal contraceptives on androgenic markers.
White T; Jain JK; Stanczyk FZ
Am J Obstet Gynecol; 2005 Jun; 192(6):2055-9. PubMed ID: 15970897
[TBL] [Abstract][Full Text] [Related]
33. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
Greco T; Graham CA; Bancroft J; Tanner A; Doll HA
Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
[TBL] [Abstract][Full Text] [Related]
34. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
Belaisch J; Hommais-loufrani B
Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
[TBL] [Abstract][Full Text] [Related]
35. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
36. Effects on blood lipid and androgen levels of two triphasic oral contraceptives.
Janaud A; Rouffy J; Upmalis D; Dain MP
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():114-6. PubMed ID: 8260968
[No Abstract] [Full Text] [Related]
37. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.
Redmond GP; Olson WH; Lippman JS; Kafrissen ME; Jones TM; Jorizzo JL
Obstet Gynecol; 1997 Apr; 89(4):615-22. PubMed ID: 9083323
[TBL] [Abstract][Full Text] [Related]
38. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
39. Metabolic aspects of the new low-dose oral contraceptives.
Chez RA
Int J Fertil; 1989 Sep; 34 Suppl():50-4. PubMed ID: 2576259
[TBL] [Abstract][Full Text] [Related]
40. Effects of low-dose oral contraceptives on body weight: results of a randomized study of up to 13 cycles of use.
Burkman RT; Fisher AC; LaGuardia KD
J Reprod Med; 2007 Nov; 52(11):1030-4. PubMed ID: 18161401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
